Ravi Shankar

Merck & Co., Inc.

Poster(s):

• (A-313) Post-authorization Safety Study to Assess the Risk of Diabetic Ketoacidosis among Type 2 Diabetes Mellitus Patients Treated with Ertugliflozin Compared to Patients Treated with Other Antihyperglycemic Agents
  Sunday, August 24, 2025

  12:00 PM - 1:30 PM ET